Home
PRME
PRME News

Latest Prime Medicine Inc. (PRME) News on November 21, 2025

Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.

22 days ago

Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them.

Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy

GlobeNewswire

22 days ago

Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

Zacks

22 days ago

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

Business Wire

4 months ago

Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy

MT Newswires

4 months ago

Prime Medicine Receives Up to $24 Million From Cystic Fibrosis Foundation

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

GlobeNewswire

4 months ago

Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

Prime Medicine to Participate in Upcoming Investor Conferences

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty

Insider Monkey

6 months ago

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty

MT Newswires

6 months ago

Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Zacks

6 months ago

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

MT Newswires

6 months ago

HC Wainwright Downgrades Prime Medicine to Neutral From Buy

MT Newswires

6 months ago

JPMorgan Downgrades Prime Medicine to Neutral From Overweight

MT Newswires

6 months ago

Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating

MT Newswires

6 months ago

Top Midday Decliners

MT Newswires

6 months ago

Wedbush Adjusts Prime Medicine Price Target to $8 From $13, Maintains Outperform Rating

MT Newswires

6 months ago

Prime Medicine to Cut Costs, Focus on Liver Treatment Programs; New CEO Named

MT Newswires

6 months ago

Prime Medicine Reports Positive Initial Data From First Patient Dosed in Potential Granulomatous Disease Drug Study

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

GlobeNewswire

6 months ago

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Zacks

6 months ago

Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire

6 months ago

Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

8 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Why Prime Medicine Stock Was Climbing Higher This Week

Motley Fool

8 months ago

Why Prime Medicine Stock Was Climbing Higher This Week

MT Newswires

8 months ago

Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating

Why Prime Medicine Stock Is Soaring Today

Motley Fool

8 months ago

Why Prime Medicine Stock Is Soaring Today

Prime sets sights on liver, lung disease as next target for its gene editing tech

BioPharma Dive

8 months ago

Prime sets sights on liver, lung disease as next target for its gene editing tech

MT Newswires

8 months ago

Prime Medicine Launches Preclinical Program for Liver Treatments

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

GlobeNewswire

8 months ago

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire

9 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

GlobeNewswire

9 months ago

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

Insider Monkey

a year ago

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

Insider Monkey

a year ago

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

Insider Monkey

a year ago

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

MT Newswires

a year ago

Prime Medicine Files for Resale of 11 Million Shares

MT Newswires

a year ago

JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a year ago

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Prime Medicine to Participate in Upcoming Investor Conferences

12 High-Growth Stocks That Could Deliver Parabolic Returns

Motley Fool

a year ago

12 High-Growth Stocks That Could Deliver Parabolic Returns

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

GlobeNewswire

a year ago

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Why I Keep Buying These 14 Incredible Growth Stocks

Motley Fool

a year ago

Why I Keep Buying These 14 Incredible Growth Stocks

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

GlobeNewswire

a year ago

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Zacks

a year ago

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Pharmaceutical Technology

a year ago

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Motley Fool

a year ago

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

MT Newswires

a year ago

Sector Update: Health Care Stocks Steady Premarket Monday

MT Newswires

a year ago

Sector Update: Health Care

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Benzinga

a year ago

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

MT Newswires

a year ago

Prime Medicine Enters Research Collaboration, License Agreement With Bristol Myers Squibb

Prime Medicine Unveils Strategically Focused Pipeline

GlobeNewswire

a year ago

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

GlobeNewswire

a year ago

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Prime to narrow gene editing research as it strikes deal with Bristol Myers

BioPharma Dive

a year ago

Prime to narrow gene editing research as it strikes deal with Bristol Myers

2 Growth Stocks That Could Make You Richer

Motley Fool

a year ago

2 Growth Stocks That Could Make You Richer

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

a year ago

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

Zacks

a year ago

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Zacks

a year ago

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?

Insider Monkey

a year ago

Prime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Zacks

a year ago

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to Trade

Prime Medicine to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Prime Medicine to Present at Upcoming Investor Conferences

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

Motley Fool

a year ago

Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio

Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks

TipRanks

2 years ago

Cathie Wood Pulls the Trigger on These 2 ‘Strong Buy’ Stocks

MT Newswires

2 years ago

HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target

MT Newswires

2 years ago

Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target

Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?

Zacks

2 years ago

Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?

MT Newswires

2 years ago

JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire

2 years ago

Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Alphabet Bought Up Two Slumping Stocks

Barrons.com

2 years ago

Alphabet Bought Up Two Slumping Stocks

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Simply Wall St.

2 years ago

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

GuruFocus.com

2 years ago

Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges with Strategic Developments

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire

2 years ago

Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

GlobeNewswire

2 years ago

Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)

What Makes Prime Medicine, Inc. (PRME) a New Buy Stock

Zacks

2 years ago

What Makes Prime Medicine, Inc. (PRME) a New Buy Stock

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

GlobeNewswire

2 years ago

Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference

Prime Medicine gets green light for trials of first-ever prime editing drug

Clinical Trials Arena

2 years ago

Prime Medicine gets green light for trials of first-ever prime editing drug

MT Newswires

2 years ago

Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance

Prime gets FDA green light to begin first trial test of ‘prime editing’

BioPharma Dive

2 years ago

Prime gets FDA green light to begin first trial test of ‘prime editing’

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

GlobeNewswire

2 years ago

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

GlobeNewswire

2 years ago

Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

2 Magnificent Growth Stocks With Room to Run

Motley Fool

2 years ago

2 Magnificent Growth Stocks With Room to Run

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

InvestorPlace

2 years ago

Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire

2 years ago

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

14 Stocks With Heavy Insider Buying In 2024

Insider Monkey

2 years ago

14 Stocks With Heavy Insider Buying In 2024

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire

2 years ago

Prime Medicine to Participate in Upcoming Investor Conferences

With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors

Simply Wall St.

2 years ago

With 34% ownership, Prime Medicine, Inc. (NASDAQ:PRME) has piqued the interest of institutional investors

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

2 years ago

Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Prime Medicine Announces Pricing of Upsized Public Offering

GlobeNewswire

2 years ago

Prime Medicine Announces Pricing of Upsized Public Offering

Prime Medicine Announces Proposed Public Offering of Common Stock

GlobeNewswire

2 years ago

Prime Medicine Announces Proposed Public Offering of Common Stock

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

2 years ago

Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire

2 years ago

Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner

Business Wire

2 years ago

Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner

SPX Technologies, Inc. (SPXC) Soars to 52-Week High, Time to Cash Out?

Zacks

2 years ago

SPX Technologies, Inc. (SPXC) Soars to 52-Week High, Time to Cash Out?

Argus Research

2 years ago

Daily – Vickers Top Buyers & Sellers for 01/29/2024

Director Laura Whitley Acquires 2,000 Shares of Texas Capital Bancshares Inc (TCBI)

GuruFocus.com

2 years ago

Director Laura Whitley Acquires 2,000 Shares of Texas Capital Bancshares Inc (TCBI)

Insider Sell: Couchbase Inc's SVP & Chief Revenue Officer Huw Owen Disposes of Shares

GuruFocus.com

2 years ago

Insider Sell: Couchbase Inc's SVP & Chief Revenue Officer Huw Owen Disposes of Shares

Energy & Utilities Roundup: Market Talk

The Wall Street Journal

2 years ago

Energy & Utilities Roundup: Market Talk

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

GlobeNewswire

2 years ago

Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis

Energy Fuels (UUUU) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks

2 years ago

Energy Fuels (UUUU) Stock Slides as Market Rises: Facts to Know Before You Trade

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

Zacks

2 years ago

Washington Trust Bancorp (WASH) Surpasses Q4 Earnings Estimates

Share on Social Networks: